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Development of transplant vasculopathy is a major cause of graft loss and mortality 
in solid organ transplant recipients. Previous studies in mice have indicated 
that vanin-1, a member of the vanin protein family with pantetheinase activity, 
is possibly involved in neointima formation. Here we investigated if RR6, a recently 
developed vanin inhibitor, could prevent development of transplant vasculopathy.
Abdominal allogeneic aorta transplantation from Dark Agouti to Brown Norway 
rats was performed. Neointima formation, leukocyte inﬁ ltration and intimal 
smooth muscle cell (SMC) proliferation was assessed and quantiﬁ ed 
histopathologically. In vitro, the effects of RR6-treatment on proliferation 
(WST-1 assay) and cytokine-induced apoptosis (ﬂ owcytometry) of SMC were 
investigated.
RR6-treatment signiﬁ cantly reduced neointima formation by 37 to 47%. Intimal 
SMC proliferation and inﬁ ltration by inﬂ ammatory cells in vivo were not altered 
by vanin inhibition. Inhibition of vanin did not induce PPARγ expression in SMC 
in vivo and in vitro. In vitro, RR6 inhibited PDGF- but not multiple cytokine-induced 
proliferation of human aortic SMC. RR6 could protected SMC from TNF-α-
induced apoptosis. 
Pharmacological inhibition of vanin activity attenuates development of transplant 
vasculopathy, most likely by preventing SMC proliferation and apoptosis. 
This study identiﬁ es vanin inhibition as potential treatment modality to prevent 
development of transplant vasculopathy.
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Introduction
Transplantation of solid organs has become the treatment of choice for several 
end-stage organ diseases like end-stage heart disease and chronic kidney 
disease. Since the introduction of potent immunosuppressants, acute rejection 
plays only a minor role in transplant medicine. Chronic rejection and cytotoxic 
side effects of drugs are main reasons for chronic transplant dysfunction (CTD)
and graft loss [1,2]. Histologically, CTD is reﬂ ected by intimal thickening, 
neointimal smooth muscle cell (SMC) proliferation and medial SMC apoptosis 
which is deﬁ ned as transplant vasculopathy (TV) [3]. This progressive blood 
vessel occlusion leads downstream to ischemic tissue damage and is therefore 
generally  accepted as main cause of CTD. Despite numerous investigations on 
prevention of TV development, adequate clinical treatments are still lacking [4].
The pathogenesis of TV appears to be a multifactorial event. Beside alloreactive 
immune responses with recruitment of monocytes and T lymphocytes, 
alloantigen-independent factors also seem to be associated with neointima (NI) 
formation [5]. At the site of the activated vascular endothelium, leukocytes are 
recruited into the intima of the graft. Proinﬂ ammatory cytokine release promotes 
medial SMC migration into the intima, but on the other hand also causes medial 
SMC apoptosis. Migrated SMC are able to proliferate and produce proinﬂ ammatory 
cytokines as well as extracellular matrix, thereby forming an oclusive NI [6,7].
Vanin-1 is a glycosyl-phosphatidylinositol-linked plasma membrane 
pantetheinase ectoenzyme and is known to be involved in stress responses and 
inﬂ ammation [8-10]. Vanin increases cellular stress by generating cysteamine 
which itself suppresses gammaglutamylcysteine synthase, the rate-limiting 
enzyme for synthesis of the antioxidant glutathione (GSH) [11,12] and decreases 
the reactive oxygen species-detoxifying enzymes superoxide dismutase and 
glutathione peroxidase [13]. As a result, in Vnn1 knock-out mice lower levels
of cysteamine are observed leading to a higher GSH-production and 
higher resistance to oxidative stress in vitro and in vivo [12,14]. Vanin-1 
expression is dependent on the transcription factor PPAR-α and was found to 
affect lipid metabolism [15,16]. Vanin-1 is known to promote inﬂ ammation at least 
partly by suppressing the expression and transduction of the anti-inﬂ ammatory 
transcription factor PPARγ [9,17]. Vnn1 knock-out mice show higher PPARγ 
levels in vitro and less NI formation to carotid artery ligation in vivo [18]. The 
pathogenesis of TV development, however, is different from the vascular injury 
model used in that study and the pathophysiological role of vanin cannot be 
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directly extrapolated to TV. 
The objective of the current study was to examine the role of vanin activity in TV 
using our recently synthesized novel vanin inhibitor RR6 [19]. RR6 is a potent 
compound with favorable pharmacokinetic, pharmacodynamic and toxicological 
properties in rats [16,19]. In keeping with the notion that Vnn1 knock-out leads to 
less NI formation in mice after arterial injury and the favorable properties of RR6 
we here investigated the potential beneﬁ t of pharmacological vanin inhibition on 
TV development in a rat aortic transplant model.




The ﬂ uorimetric vanin substrate AMC-Pan was a kind gift of 
Dr. Francesco Pinnen (Department of Pharmacy, “G. d’Annunzio” University, 
Chieti-Pescara, Italy) and was prepared as described previously [19]. The 
vanin inhibitor RR6, that we described recently [19], was obtained from 
Chiralix B.V. (Nijmegen, The Netherlands). RR6 was stored as a pure oil at 
-20°C. The stability in aqueous solution was tested for long-term experiments in 
animals. No degradation was observed (as assessed by LC-MS) after storage of 
an aqueous solution of RR6 with a concentration of 30 mg/ml for 6 weeks at 8°C.
Rats
Male Dark Agouti (DA) and Brown Norway (BN) rats were obtained from Janvier 
(Saint-Berthevin, France). Rats (weighing 230-260 g) were kept under clean 
conventional conditions and were fed standard rat chow ad libitum. Vehicle or 
RR6 was administered orally in drinking water ad libitum. All animals received 
humane care in compliance with the ‘Principles of Laboratory Animal Care’ 
(NIH Publication No. 86-23, revised 1985) and the ‘Dutch Law on Experimental 
Animal Care’ and were approved by the animal ethics committee of the University 
of Groningen (DEC 6624C).
Experimental groups
To study the inﬂ uence of RR6 on TV development, orthotopic aortic transplantation 
from DA to BN rats was performed. Rats received either RR6 (3 mg/ml RR6 in 
10% MiliQ water and 90% tapped water) or vehicle 24 hours before to 
transplantation till the end of the study. After the follow-up of 2 or 4 weeks rats 
were sacriﬁ ced and grafts were analyzed. 
Aorta transplantation
Aortic allografts (10-12 mm) were transplanted as described previously [20]. 
Brieﬂ y, the abdominal aorta between the left renal artery and the bifurcation 
was removed from the donor rat and perfused with saline to remove blood cells. 
After 1 hour of cold storage in 0.9% saline, the aortic graft was orthotopically 
transplanted into the recipient rat via end-to-end anastomosis using 9-0 nylon 
suture. Total warm ischemic time was consistently 25 minutes. Recipient rats did 
not receive anti-rejection therapy.
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Assessment of serum vanin activity
Biological activity of RR6 in vivo was monitored by measuring serum vanin activity 
ex vivo. Brieﬂ y, blood samples were obtained before treatment, at transplantation, 
after half way follow-up (i.e. 1 week [for 2 weeks follow-up] and 2 weeks 
[for 4 weeks follow-up] after transplantation) and at autopsy. Serum was isolated 
and stored at -20°C until analysis. Pantetheinase activity was measured 
largely as described by Ruan et al. [21]. AMC-Pan-substrate was dissolved in 
90% ethanol/PBS at a concentration of 10 µM. 20 µl substrate solution was 
evaporated to dryness in 96-well plates. Rat serum samples (20 µl) were added 
and substrate hydrolysis was allowed to proceed. From these reaction mixtures 
10 μl was taken after 10 min of incubation, diluted 20-fold in PBS, and measured 
in a 96-well plate ﬂ uorescence reader (LS55, Perkin-Elmer) at excitation 360 nm 
and emission 450 nm.
Quantitation of transplant vasculopathy
Grafts removed at autopsy were ﬁ xed in formalin and embedded in parafﬁ n. Tissue 
sections (3 µm) were cut at the middle of the graft as well as 500 µm and 1000 µm 
distant from the middle. Sections were stained according Van Gieson to visualize 
elastin ﬁ bers. Slides were scanned on a digital slide scanner (ScanScope CS2)
and analyzed using ImageScope 11.2 (both Aperio, Vista, USA). Surface of 
NI was measured by subtracting lumen area from internal elastic lamina area. 
To normalize for graft size the ratio of neointima/media of each graft was 
calculated. Three sections per anatomical location in the graft were measured 
and the mean calculated. Per graft, a total of 9 sections was quantiﬁ ed and the 
mean of the three anatomical locaions was calculated.
Immunohistochemistry
To assess inﬂ ammatory cell inﬁ ltration, allografts (removed 2 weeks after 
transplantation) were analyzed for the prensence CD3+ and CD68+ cells. 
To this end, 3 µm formalin-ﬁ xed parafﬁ n sections were deparaﬁ nizied followed by 
heat-induced epitope retrieval (HIER) in 0.1 M Tris/HCl pH 9.0 at 80°C overnight. 




 in PBS. Next, sections 
were incubated with rabbit-anti-human-CD3 (clone IS503, Dako, Heverlee, 
Belgium) or mouse-anti-rat-CD68 (clone ED1, AbD serotec, Colmar, France). 
Staining was visualized with goat-anti-rabbit-HRP (for CD3) or goat-anti-mouse-
HRP (for CD68) and rabbit-anti-goat-HRP (all from Dako, Heverlee, Belgium) 
Inhibition of vanin attenuates transplant vasculopathy in rat aortic allografts
203
using 3,3′-diaminobenzidine (DAB) as chromogen. Nuclei were counterstained 
with Mayer’s hematoxylin. 
To detect proliferating SMC in aortic allografts (harvested 4 weeks after 
transplantation) double-staining immunohistochemistry for Ki67 and αSMA 
expression was performed. HIER and endogeous peroxidase blocking was 
performed as descibed above. Staining for Ki67 (rabbit-anti-human-Ki67 polyclonal
antibody, clone NCL-Ki67p, Novocastra, Leica, Rijswijk, The Netherlands) and 
αSMA (mouse-anti-human-αSMA, clone 1A4, Dako, Heverlee, Belgium) were 
performed sequentially. Anti-human-Ki67 binding was visualized with goat-
anti-rabbit-HRP and rabbit-anti-goat-HRP (both from Dako, Heverlee, Belgium) 
using DAB. Anti-human-αSMA binding was visualized using goat-anti-mouse-AP
and FastRed (Life Technologies, Bleiswijk, The Netherlands). Nuclei were 
counterstained with Mayer’s hematoxylin and sections were coverslipped in 
Kaiser’s glycerol-gelatin.
To assess PPARγ expression in medial and neointimal SMC (in grafts harvested 
4 weeks after transplantation), sections were deparafﬁ nized and HIER performed 
in boiling 10 mM citric acid pH 6.0 for 15 min. Next, sections were incubated with 
rabbit-anti-human-PPARγ (clone H-100, Santa Cruz Biotechnology, Heidelberg, 
Germany) and the staining was continued as described above for Ki67. All slides 
were scanned on a digital slide scanner (Nanozoomer 2.0HT, Hamamatsu, 
Almere, The Netherlands). Ki67 expression of αSMA positive cells was analyzed 
using HistoQuest software (Version 3.5.3.0171, Tissuegnostics, Vienna, Austria). 
CD3 and CD68 positivity was analyzed using the positive pixel count v9 algorithm 
by ImageScope 11.2 (Aperio, Vista, USA). Data is expressed in positive pixel 
counts/area.
Cell culture
Human aortic smooth muscle cells (haSMC) were purchased from ScienCell 
(ScienCell Research Labortories, Carlsbad, USA) and were grown in SMC growth 
medium (ScienCell Research Laboratories, Carlsbad, USA) including SMC 
growth supplement, 2% FBS, 100 U/ml penicillin and 100 U/ml streptomycin. 
Starvation medium was deﬁ ned as SMC basal medium supplemented with 
0.1% FBS and antibiotics.
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Protein isolation and Western blot analysis
Cytoplasmatic and nuclear extracts were prepared as previously described [22].
Brieﬂ y, cells were incubated in 100 µl buffer A (10 mM HEPES pH 7.9, 
10 mM KCl, 1.5 mM MgCl
2
, 0.5 mM dithiothreitol, 10 ng/μl aprotinin and 
10 ng/μl leupeptin) for 10 min on ice. After addition of 0.1% (v/v) Nonidet P-40 
cells were vortexed for 10 seconds and subequently centrifuged (14,000 xg, 
10 min, 4°C). Supernatant (cytosolic fraction) was stored at -20°C till analysis and 
pellet resuspended in 50 μl of buffer B (20 mM HEPES pH 7.9, 25% (v/v) glycerol, 
420 mM NaCl, 1.5 mM MgCl
2
, 0.2 mM EDTA, 0.5 mM phenylmethylsulfonyl 
ﬂ uoride, 0.5 mM dithiothreitol, 10 ng/μl aprotinin and 10 ng/µl leupeptin). Samples 
were incubated on ice for 10 min while shaking. After centrifugation (14,000 xg, 
10 min, 4°C) the supernatant was stored at -20°C till analysis (nuclear fraction). 
Protein concentrations were measured using Coomassie-Reagent (Pierce, 
Rockford, USA). Samples (20 µg protein extract) were heated to 95°C for 5 min, 
loaded and separated on 10-20% SDS-polyacrylamide gels followed by semi-dry 
blotted onto PVDF membranes (Roche, Mannheim, Germany). Staining of blots 
was performed by standard operating procedures using anti-PPARγ antibody 
(clone H-100, Santa Cruz Biotechnology, Heidelberg, Germany). To conﬁ rm 
equal protein loading, membranes were re-probed with monoclonal anti-GAPDH 
antibody (clone mAbcam 9484, Abcam, Cambridge, UK).
haSMC proliferation assay
haSMC were seeded in 96-well ﬂ at bottom culture plates at a density of 
1.5×104 cells/well. Plated cells were allowed to attach for 24 hours and 
synchronized for additional 24 hours in starvation medium. Subsequently, 
cells were stimulated for 72 hours with SMC stimulation medium in the absence or 
presence of different concentrations of RR6 (range 0-50 µM). After adding WST-1 
(Roche Diagnostics, Mannheim, Germany) for the last 2.5 hours of culture, 
colored formazan was quantiﬁ ed by an ELISA plate reader (Varioskan, 
Thermo Scientiﬁ c, Erembodegem-Aalst, Belgium) at 450 nm. Results are 
expressed as absorbance at 450 nm ± SD of six different experiments. 
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haSMC apoptosis assay
haSMC were plated in 6-well culture plates in SMC growth medium as described 
above at a density of 105 cells/well. Plated cells were allowed to attach for 
24 hours, starved for additional 24 hours and subsequently stimulated with 
SMC growth medium in the presence or absence of different concentrations of 
RR6 (0-50 µM) and/or 10 ng/ml TNF-α for 6 hours. Positive control was obtained 




 to the culture for 4 hours. Cells were trypsinized, washed 
in PBS twice and stained with anti-Annexin V antibody (a marker for apoptosis 
as well as other forms of cell death) and 7AAD (a marker for late apoptosis and 
necrosis) (both Biolegend, San Diego, USA) according the supplier’s protocol. 
Fluorescence was assessed on a FACS Calibur ﬂ ow cytometer (BD Bioscience, 
Breda, The Netherlands) within the same day. At least 50,000 gated events were 
collected per sample and data was analyzed using Flowjo software (Version 10.5, 
Tree Star, Ashland, USA).
Statistical analysis
Data is expressed as mean ± standard deviation (SD). Statistical analysis was 
performed using Student’s t-test with previous testing of normal distribution. 
For analysis of drinking water intake, the two-way ANOVA was chosen. A p-value 




Figure 1: RR6 inhibits vanin activity.
A: Daily water/drug intake of each rat was assessed. Note the signiﬁ cant higher water intake at ﬁ rst 
day after transplantation (***p<0.001 compared to the volume of vehicle (water) at same time-point). 
In the remaining follow-up period, a trend towards a higher water intake was observed. However,
this did not reach statistical signiﬁ cance.
B: A blood sample was drawn and vanin activity was measured 2 days prior to transplantation, at the 
day of transplantation, halfway the experiment and after complete follow-up time as described in the 
Methods section (***p<0.001 compared to vehicle control at same time-point). 
C: Body weight during follow-up period.
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RR6 inhibits vanin activity
Starting at day -1 (before transplantation) RR6 or vehicle was administered and 
uptake was monitored for 2 or 4 weeks. RR6 containing drinking water was 
replaced at least every third day to prevent contamination or decomposition of 
RR6. At the ﬁ rst post-operative day, the volume of water uptake under 
RR6-treatment was signiﬁ cantly increased. This effect was normalized after 
24 hours and drinking uptake did not signiﬁ cantly differ between treatment and 
control (Figure 1A). Assessment of serum vanin activity showed low interindividual 
variation. After 24 hours of RR6-treatment, serum vanin activity was almost 
completely blocked and remained low (less than 90% of the control value) until 
the end of the experiment. In the control (vehicle) group vanin activity was not 
affected (Figure 1B). RR6-treatment did not affect body weight (Figures 1C). 
Figure 2: Vanin inhibition reduces neointima formation in aortic allografts.
Aortas harvested 4 weeks after transplantation were stained according Verhoeff’s van Gieson.
A: Representative aortas are depicted. 
B: Area of NI was assessed by subtracting the lumen area from inner border of elastin layer. Statistics 
are performed on 3 slides at the middle of the graft and 3 slides cut 500 µm respectively 1000 µm 
further into the graft. Neointima surface area (left panel) and neointima normalized to the graft size by 
dividing by media area (right panel) is given.
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Inhibition of vanin activity reduces neointima formation
Two weeks following transplantation neointima (NI) formation was minimal in 
either group (data not shown). In the group that was studied up to four weeks 
following transplantation, a concentric neointima was formed (Figure 2A). 
RR6-treatment signiﬁ cantly reduced NI formation as shown in ﬁ gure 2B. When 
the total neointima was measured, a 47.2% reduction was found. Upon correction 
for the graft size (area normalized to the size of the graft, division by the 
media area) a 36.6% reduction of NI formation was observed. 
Inhibtion of vanin activity does not inﬂ uence smooth muscle-like cell 
proliferation in vivo
To assess the amount of intimal smooth muscle-like cells (SMLC) and their 
proliferation rate in the NI, a double staining for Ki67 and αSMA was performed. 
Speciﬁ city of primary antibodies was evaluated in single stainings (Figure 3A). 
Double staining was analyzed using HistoQuest software (Figure 3B). Positivity 
of cells was determined by gating in dotplots (Figure 3B, left panel) and 
correct cut-offs were set using backward data gating (Figure 3B, right panel). 
For accuracy, only the NI of complete cross-sections were analyzed (Figure 3C). 
Statistics of six sections (three sections cut in the middle and 500 µm further 
respectively) per graft revealed that 55% of all cells expressed αSMA (Figure 3D) 
while the relative number of αSMA expressing cells was slightly higher under 
RR6-treatment. Nuclear Ki67 expression of αSMA positive cells was comparable 
in both groups (8.4% vs. 8.6% [Figure 3E]).
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Figure 3: Vanin inhibition does not affect quantity of intimal αSMA+ cells or their proliferation rate.
A double staining for αSMA (FastRed-red) and the proliferation marker Ki67 (DAB-brown) 
was performed and analyzed by an automated cell recognition software (HistoQuest, Tissuegnostics, 
Vienna, Austria). Only cells in the NI were assessed. 
A: Speciﬁ city of primary antibodies was controlled in single stainings. 
B: Nuclei of cells were recognized automatically and cut-offs for positivity of each marker were 
determined by gating on dot plot (left). Correct gating was controlled using the backward data function. 
Positive recognized cells are highlighted in red, negative in green (right). 
C: A representative cross-section of a graft is depicted. 
D+E: Statistics were performed on 3 slides from the middle of the graft and 3 slides cut 500 µm 
further into the graft. The total amount of SMLC (intimal αSMA+  cells) (D) and proliferating SMLC 
(intimal αSMA+Ki67+ cells) (E) are depicted.
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Inhibition of vanin activity does not impair T cell or macrophage inﬁ ltration
Inﬁ ltration of T cells and macrophages in the grafts harvested 2 weeks after 
transplantation was determined by analyzing CD3 and CD68 expression 
respectively. CD3 was expressed predominantly in the adventitia and revealed 
10.4% positive pixel counts (Figure 4A+B). RR6-treated recipients had a 
non-signiﬁ cant trend towards lower CD3 positivity (8.5%) in the grafts. In 
addition to adventitial inﬁ ltration, CD68+ cells were also clearly present in the 
subendothelial space (Figure 4C+D). CD68 positivity did not differ between the 
RR6- and vehicle-treated groups.
.
Figure 4: Inﬂ ammatory inﬁ ltration of T cells and macrophages in RR6-treated aortic allografts.
To assess inﬂ ammatory inﬁ ltration of the graft harvest 2 weeks after transplantation, stainings for CD3 
and CD68 were performed. 
A: T cell inﬁ ltration, represented by CD3 staining, of representative grafts are depicted. 
B: Statistics were performed on 3 slides from the middle of the graft and 3 slides cut 500 µm further 
into the graft. Ratio of positive/total pixels of whole graft, containing NI, media and adventitia but 
excluding surrounding tissue, was assessed. 
C: Macrophage inﬁ ltration, represented by CD68 (ED-1) staining, of representative grafts are depicted.
D: Statistics were performed as described in B.
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Vanin inhibition does not inﬂ uence PPARγ activity
PPARγ activation is known to suppress SMC proliferation and migration 
in vitro [23] and attenuates SMC invasiveness and neointima formation after 
arterial injury or in chronic rejection models in vivo [24,25]. Dammanahalli et al. 
showed an up-regulation of PPARγ in Vnn1 knock-out mice [18]. To investigate if 
inhibition of vanin activity also results in higher expression levels of PPARγ, aortas 
harvested at week 4 were stained for PPARγ expression. While in fatty tissue 
a high nuclear PPARγ expression was observed (positive control; Figure 5A),
Figure 5: Vanin inhibition does not affect PPARγ activation or expression in SMC.
To investigate PPARγ activation in SMC in vivo, a double staining of PPARγ (DAB-brown) and αSMA 
(FastRed) was performed on 4 weeks followed-up aortas. 
A: Adipocytes served as positive control. 
B: High magniﬁ cation of a representative RR6-treated graft. No nuclear PPARγ could be detected 
in intimal or medial SMC, neither in the RR6-treated nor untreated group (L: lumen, NI: neointima, 
M: media, A: adventitia). 
C: To investigate PPARγ induction in vitro, haSMC were starved for 24 hours and subsequently 
stimulated with growth supplement in the presence or absence of 50 µM RR6 for up to 3 days. 
Cytoplasmic and nuclear proteins were isolated and Western blotting was performed. 2 independent 
experiments with essentially the same results were performed.
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no PPARγ expression could be detected in the NI, neither in the presence nor 
absence of RR6 (Figure 5B).
To investigate this further in vitro, human aortic SMC (haSMC) were starved for 
24 hours and subsequently stimulated with growth factors in the presence or 
absence of RR6 for up to 3 days (Figure 5C). Cytoplasmic and nuclear proteins 
were isolated and investigated for PPARγ levels. Hardly any PPARγ expression 
could be detected in the cytoplasmic fraction. In the nuclear fraction, a constant 
level of PPARγ was detectable at 24, 48 and 72 hours. RR6 did not inﬂ uence 
PPARγ levels.
RR6 inhibits PDGF-induced proliferation and protects SMC from cytokine-
induced apoptosis
In order to study the mechanism of reduced neointima formation in more detail, 
we investigated the proliferation rate of haSMC. To this end, cells were stimulated 
with a cocktail of growth factors (“growth supplement”; consisting of insulin, 
apo-transferin, hydrocortisone, insulin-like growth factor 1 [IGF-1] and 
ﬁ broblast growth factor [FGF] [Figure 6A]) or PDGF (Figure 6B). Both treatments 
resulted in an increased haSMC proliferation. While RR6-treatment inhibited 
proliferation of PDGF-stimulated haSMC, RR6 had no inﬂ uence on growth 
supplement-induced proliferation.
haSMC are very sensitive to overstimulation by various proinﬂ ammatory 
cytokines. In untreated cells approximately 7% of all cells are Annexin V+ and 
7AAD-. Stimulation with 10 ng/ml TNF-α resulted in an apoptosis rate of 14%. 
Addition of the vanin inhibitor RR6 caused a dose-dependent reduction of the 
apoptosis rate to control levels at 50 µM RR6 (Figure 6C+D).
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Figure 6: RR6 inhibits PDGF-induced proliferation and protects haSMCs against TNF-α-
induced apoptosis.
A: haSMC were stimulated for 72 hours with growth supplement (containing insulin, apo-transferin, 
hydrocortisone, IGF-1 and FGF) in the presence or absence of different concentrations of RR6. Cells 
starved for the same period served as negative control (medium). Proliferation was assessed using 
the WST-1 proliferation assay. The results of a representative experiment are depicted and represent 
absorbance of formazan ± SD of 6 replicate wells for each condition (n.s. not signiﬁ cant). A total of 
4 independent experiments were performed. 
B: haSMC were stimulated for 72 hours with 10 ng/ml PDGF in the presence or absence of different 
concentrations of RR6. Cells starved for the same period served as negative control (medium). 
Proliferation was assessed as described in A (n.s. not signiﬁ cant). A total of 3 independent experiments 
were performed. 
C: haSMC were stimulated for 6 hours with 10 ng/ml TNF-α in the presence or absence of different 
concentrations of RR6. In the medium control (no TNF-α or RR6-treatment) a background apoptosis 
level of 7% was detected. In the presence of 10 ng/ml TNF-α a clear apoptotic population of 
Annexin V+7AAD- cells was induced. Additional RR6-treatment prevented induction of apoptosis 
completely. 
D: The results of 4 independent experiments are depicted and represent percentage of 




The present study was conducted to investigate if pharmacological inhibition of 
vanin by RR6 prevents the development of TV in allogeneic aorta transplanted 
rats. The results are the following. Firstly, RR6-treatment resulted in signiﬁ cantly 
less NI formation after 4 weeks. Composition of NI did not differ in αSMA positivity 
between RR6-treatment and vehicle control. Intimal SMC proliferation rate, 
assessed by nuclear Ki67 expression, was not inﬂ uenced by vanin inhibition. 
Secondly, inﬂ ammatory inﬁ ltration by T cells and macrophages in the grafts 
2 weeks after transplantation was not altered by RR6-treatment. PPARγ was 
not induced by vanin inhibition in vivo and in vitro. Vanin inhibition prevented 
PDGF-induced, but not multiple cytokine-induced, proliferation of haSMC. 
Importantely, RR6-treatment protected haSMC from cytokine-induced 
apoptosis.
Dammanahalli et al. showed that in a vascular injury model in Vnn1 knock-out mice, 
NI formation was completely prevented [18]. In our study we also found 
a signiﬁ cant reduction of NI formation, but this reduction was incomplete and some 
NI formation was still present. Dammanahalli et al. used the clipped carotid artery 
model, and vascular remodelling was analyzed after 3 weeks of follow-up [18]. 
In our model, NI formation is triggered by an alloreactive, inﬂ ammation-driven 
and permanent stimulus. Other differences between the two models are caused 
by the genetic versus pharmacological approach. In the Vnn1 knock-out mouse 
model there is still considerable pantetheinase activity present in serum due to 
the presence of vanin-3 activity [18]. In our rat model, pantetheinase activity 
(as measured with the AMC-Pan substrate) is blocked for >90% over the entire 
test period. In case that NI formation is completely dependent on vanin-1 activity 
rather than vanin-3 activity, the mouse model will show a stronger effect because 
vanin-1 activity is completely absent. Notwithstanding the differences between 
the two models, both studies support the concept that inhibition of vanin activity 
reduces NI development and that a pharmacological approach may be beneﬁ cial 
to limit transplant vasculopathy.
Different studies showed that inhibition of SMC proliferation results in less NI 
formation [20]. In vitro, PDGF-induced proliferation was impaired in the presence 
of RR6, whereas proliferation induced with a cocktail of pro-proliferative cytokines 
(consisting of insulin, apo-transferin, hydrocortisone, IGF-1 and FGF) was not 
inﬂ uenced by vanin inhibition. In vivo, proliferation rate of intimal SMC, assessed 
by Ki67 expression, was not impaired. 
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Wang et al. showed that beside PDGF also other cytokines like Interferon (IFN)-γ
stimulates SMC proliferation and therewith NI formation [26]. Moreover, 
deﬁ ciency of IFN-γ prevents development of a NI [27,28]. Inhibition of PDGF-
induced proliferation could therefore partly contribute to a lower intimal SMC 
proliferation rate but is not able to block complete intimal proliferation.
SMC are very sensitive to chemokines and react to an overstimulation by 
proinﬂ ammatory cytokines with apoptosis resulting in activation of endothelial 
cells attracting macrophages leading to more inﬂ ammatory inﬁ ltration [29,30]. 
Inhibition of SMC apoptosis is known to break this vicious circle and to attenuate 
NI formation [31]. We could show that inhibition of vanin activity prevents TNF-α-
induced apoptosis in vitro. In vivo, loss of medial αSMA expression was not 
prevented by RR6-treatment indicating SMC dedifferentiation is still present. 
However, we have no clear indication that RR6 also prevents SMC apoptosis 
in vivo.
Dammanahalli et al. postulated that the mechanism of less NI formation in 
Vnn1 knock-out mice is most likely mediated via induction of PPARγ [18]. PPARγ-
inducers are well known for their beneﬁ cial effect on NI formation in TV but also in 
atherosclerosis [32]. However, we could not detect PPARγ expression in medial 
or neointimal cells in vivo using immunohistochemistry. To exclude low sensitivity 
of PPARγ staining nuclear and cytoplasmic PPARγ levels of RR6-treated 
haSMC were analyzed in vitro. PPARγ expression remained equal over time and 
additional inhibition of vanin did not inﬂ uence PPARγ expression. It is still possible 
that PPARγ induction was prevented by residual vanin-1 activity in our model or 
that PPARγ activation was an unrelated side effect of the knock-down approach 
in mice. As we still observe a signiﬁ cant reduction of NI in our model this suggests 
that the mechanism of NI reduction is not fully dependent of PPAR activity.
Development of TV is a multifactorial event that includes alloreactive immune 
responses and non-immunological factors. The present study focus was 
on SMC behaviour in the presence of vanin inhibition. NI formation in 
aortic transplantation can also be completely prevented by immunosuppression, 
e.g. with the calcineurin inhibitor cyclosporine A [33,34]. As inﬂ ammatory 
inﬁ ltration of the graft did not differ between RR6-treatment and vehicle control, 
it is unlikely that reduction of NI formation is due to immunosuppression on 
T cells or macrophages. However, endothelial cells are now regarded as 
key player in the induction of the development of chronic rejection [35]. It remains 
to be determined how inhibition of vanin affects endothelial cells and other 
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inﬁ ltrating cells, e.g. neutrophil granulocytes, that modulate vascular remodelling.
To conclude, in the present study we demonstrate that inhibition of vanin 
signiﬁ cantly lowers NI formation in an experimental model for TV. Attenuation 
of NI formation was most likely mediated via inhibition of PDGF-induced 
SMC proliferation and reduction of cytokine-induced SMC apoptosis. In 
conjunction with the absence of adverse effects upon long-term administration of 
RR6, these data clearly warrant further studies to design and test next generation 
vanin inhibitors that are potent, speciﬁ c and safe, and can be used as a potential 
novel therapy to prevent chronic allograft loss. 
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